{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:42:03Z","timestamp":1785462123295,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtcvsonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jtcvs.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T21:18:34Z","timestamp":1665177514000},"page":"828-839.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non\u2013small cell lung cancer"],"prefix":"10.1016","volume":"165","author":[{"given":"Valerie W.","family":"Rusch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Alexander","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salama N.","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Toloza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Haura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Raz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Reckamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Merritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight H.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Finley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciaran J.","family":"McNamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Blasberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Doebele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Baciewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Kris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtcvs.2022.10.007_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the eighth edition of the TNM classification of malignant tumors","volume":"11","author":"Goldstraw","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(15)60294-X","article-title":"Induction chemoradiation in stage IIIA\/N2 non-small cell lung cancer: a phase 3 randomised trial","volume":"386","author":"Pless","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1200\/JCO.1995.13.8.1880","article-title":"Concurrent cisplatin\/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805","volume":"13","author":"Albain","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jnci\/djk093","article-title":"Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer","volume":"99","author":"Van Meerbeeck","year":"2007","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib5","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1200\/JCO.2009.26.1685","article-title":"Surgery with or without preoperative paclitaxel and carboplatin in early stage non-small cell lung cancer: Southwest Oncology Group trial S9900, an intergroup, randomized, phase III trial","volume":"28","author":"Pisters","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1056\/NEJM199401203300301","article-title":"A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer","volume":"330","author":"Rosell","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(98)00046-4","article-title":"Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer","volume":"21","author":"Roth","year":"1998","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib8","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0003-4975(93)91072-U","article-title":"Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients","volume":"55","author":"Martini","year":"1993","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib9","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5223(00)70120-6","article-title":"Induction chemotherapy before surgery for early-stage lung cancer: a novel approach","volume":"119","author":"Pisters","year":"2000","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"Suppl 1","key":"10.1016\/j.jtcvs.2022.10.007_bib11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/0169-5002(95)00420-6","article-title":"Effectiveness and toxicity of preoperative therapy in stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (clinical N2)","volume":"12","author":"Kris","year":"1995","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","author":"Burdett","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22\/NVALT 2\/EORTC 08012 multicentre randomised trial and update of systematic review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jtcvs.2022.10.007_bib14","first-page":"S224","article-title":"Adjuvant or neoadjuvant chemotherapy for NSCLC","volume":"6","author":"McElnay","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib15","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways. Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib18","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib19","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib21","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib23","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib24","doi-asserted-by":"crossref","first-page":"e11936","DOI":"10.1097\/MD.0000000000011936","article-title":"Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer","volume":"97","author":"Khan","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib25","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jtho.2018.04.039","article-title":"Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"13","author":"Fehrenbacher","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib27","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOASTAR trial","volume":"27","author":"Cacsone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib29","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (sinitilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"Suppl 15","key":"10.1016\/j.jtcvs.2022.10.007_bib32","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab + platinum-doublet chemotherapy vs chemotherapy alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer","volume":"39","author":"Spicer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib33","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/JTO.0b013e3181a0d82e","article-title":"The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer","volume":"4","author":"Rusch","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib35","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small cell lung cancers: proposals for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib36","unstructured":"CTCAE, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v.4.03; 2010. Accessed April 1, 2022. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer\u2013a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib38","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant treatment of non-small cell lung cancer with atezolizumab","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib39","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.athoracsur.2021.06.069","article-title":"Surgical perspective on neoadjuvant immunotherapy in non-small cell lung cancer","volume":"114","author":"Lee","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","article-title":"Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup trial 0160)","volume":"25","author":"Rusch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtcvs.2022.10.007_bib41","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","article-title":"Initial experience with lung cancer resection after treatment with T-cell checkpoint inhibitors","volume":"104","author":"Chaft","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.jtcvs.2022.10.007_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100016","article-title":"Video-assisted thoracoscopic or open lobectomy in early-stage lung cancer","volume":"1","author":"Lim","year":"2022","journal-title":"NEJM Evid"}],"container-title":["The Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522322010558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022522322010558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:46:36Z","timestamp":1784133996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022522322010558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0022522322010558"],"URL":"https:\/\/doi.org\/10.1016\/j.jtcvs.2022.10.007","relation":{},"ISSN":["0022-5223"],"issn-type":[{"value":"0022-5223","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non\u2013small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Thoracic and Cardiovascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtcvs.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery","name":"copyright","label":"Copyright"}]}}